Pyrazolopyrimidines

1995 Walsh, 1999, Engelhart CL The direct economic costs of insomnia in the United States for 1995, Sleep, 22, S386 Young AB Chu, 1990, Distribution of GABAA and GABAB receptors in mammalian brain: potential targets for drug development, Drug Dev Res, 21, 161, 10.1002/ddr.430210303 Whiting, 1995, Structure and pharmacology of vertebrate GABAA receptor subtypes, Intl Rev Neurobiol, 38, 95, 10.1016/S0074-7742(08)60525-5 Dämgen, 1999, Zaleplon displays a selectivity to recombinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines, Neurosci Res Commun, 25, 139, 10.1002/(SICI)1520-6769(199911/12)25:3<139::AID-NRC3>3.0.CO;2-W Greenblatt, 1998, Comparative kinetics and dynamics of zaleplon, zolpidem and placebo, Clin Pharmacol Ther, 64, 553, 10.1016/S0009-9236(98)90139-4 Lee, 1998 Rosen, 1999, Zaleplon pharmacokinetics and absolute bioavailability, Biopharm Drug Dispos, 20, 171, 10.1002/(SICI)1099-081X(199904)20:3<171::AID-BDD169>3.0.CO;2-K Wickland, 1999, The safety and pharmacokinetics of zaleplon in hepatically impaired patients, Sleep Res Online, 2, 5171 Wickland, 1999, The pharmacokinetics and safety of zaleplon in patients with renal impairment, Sleep Res Online, 2, 5172 European Agency for the Evaluation of Medicinal Products. Committee for Propriety Medicinal Products European Public Assessment Report (EPAR): Sonata Report number CPMP/897/99, 1999 1999 Darwish, 1999, Overview of drug-interactions with zaleplon, Sleep, 22, S280 Darwish, 1999, Analysis of potential drug interactions with zaleplon, J Am Geriatr Soc, 47, S62 Sanchez Garcia, 2000, Absence of an interaction between ibuprofen and zaleplon, Am J Health Syst Pharm, 57, 1137, 10.1093/ajhp/57.12.1137 Hetta, 2000, Psychomotor effects of zaleplon and thioridazine coadministration, Eur J Clin Pharmacol, 56, 211, 10.1007/s002280000129 Walsh, 1998, Efficacy and safety of 14 day administration of zaleplon 5 and 10 mg for the treatment of primary insomnia, Clin Drug Invest, 16, 347, 10.2165/00044011-199816050-00001 Elie, 1999, Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic: Zaleplon Clinical Study Group, J Clin Psychiatr, 60, 536, 10.4088/JCP.v60n0806 Fry, 2000, Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group, Int Clin Psychopharmacol, 15, 141, 10.1097/00004850-200015030-00003 Walsh, 2000, A 5 week polysomnographic assessment of zaleplon for the treatment of primary insomnia, Sleep Med, 1, 41, 10.1016/S1389-9457(99)00006-4 Elie, 1999, Zaleplon is effective in reducing time to sleep onset, Eur Neuropsychopharmacol, 9, S361, 10.1016/S0924-977X(99)80556-2 Hedner, 1998, Improvement in sleep latency and sleep quality with zaleplon in elderly patient with primary insomnia, J Sleep Res, 7, 115 Hedner, 2000, Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia the Zaleplon Clinical Investigator Study Group, Int J Geriatr Psychiatr, 15, 704, 10.1002/1099-1166(200008)15:8<704::AID-GPS183>3.0.CO;2-S Ancoli-Israel, 1999, Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects, J Clin Psychiatr, 1, 114 Cluydts, 2000, A 28-night evaluation of the efficacy, next effects and withdrawal potential of zaleplon and zolpidem in out-patients with primary insomnia, 14 Dietrich, 1995, Zaleplon: dose response evaluation in primary insomnia, Sleep Res, 24, A116 George, 1999, Safety and efficacy of zaleplon versus zolpidem in outpatients with chronic obstructive pulmonary disease (COPD) and insomnia, Sleep, 22, S320 Vermeeren, 1998, Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance, Hum Psychopharmacol Clin Exp, 13, S98, 10.1002/(SICI)1099-1077(1998110)13:2+<S98::AID-HUP54>3.0.CO;2-1 Troy, 2000, Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance, J Clin Psychopharmacol, 20, 328, 10.1097/00004714-200006000-00007 Walsh, 2000, Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia, Clin Neuropharmacol, 23, 17, 10.1097/00002826-200001000-00004 Allen, 1993, The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers, Eur J Clin Pharmacol, 45, 313, 10.1007/BF00265947 Beer, 1994, A placebo controlled evaluation of single escalating dose of CL284,846, a non-benzodiazepine hypnotic, J Clin Pharmacol, 34, 355, 10.1002/j.1552-4604.1994.tb02002.x Danjou, 1999, Comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening, Br J Clin Pharmacol, 48, 367, 10.1046/j.1365-2125.1999.00024.x Rush, 1999, Zaleplon and triazolam in humans: acute behavioral effects and abuse potential, Psychopharmacology, 145, 39, 10.1007/s002130051030 Scharf, 2000, Evaluation of next day functioning and residual sedation in healthy subjects: zaleplon vs flurazepam, 25 Silvilotti, 1991, GABA receptor mechanisms in the central nervous system, Prog Neurobiol, 36, 35, 10.1016/0301-0082(91)90036-Z Nayeem, 1994, Quaternary structure of the native GABAA receptor determined by electron microscopic image analysis, J Neurochem, 62, 815, 10.1046/j.1471-4159.1994.62020815.x